ACW Stock Overview
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
Actinogen Medical Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.025|
|52 Week High||AU$0.12|
|52 Week Low||AU$0.015|
|1 Month Change||56.25%|
|3 Month Change||0%|
|1 Year Change||-78.26%|
|3 Year Change||19.05%|
|5 Year Change||-48.98%|
|Change since IPO||-96.95%|
Recent News & Updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?Nov 16
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?Aug 02
We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business GrowthApr 12
We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash WiselyNov 28
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn SituationAug 09
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn SituationApr 07
We're Not Worried About Actinogen Medical's (ASX:ACW) Cash BurnOct 24
Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its BusinessJul 11
We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To GrowMar 27
How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?Jan 07
|ACW||AU Biotechs||AU Market|
Return vs Industry: ACW underperformed the Australian Biotechs industry which returned -13.3% over the past year.
Return vs Market: ACW underperformed the Australian Market which returned -3.4% over the past year.
|ACW Average Weekly Movement||14.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.8%|
|10% most volatile stocks in AU Market||17.7%|
|10% least volatile stocks in AU Market||3.1%|
Stable Share Price: ACW is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ACW's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer’s disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
|ACW fundamental statistics|
Is ACW overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACW income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.0048|
|Net Profit Margin||-219.98%|
How did ACW perform over the long term?See historical performance and comparison